Jakarta, June 1, 2025 — The Indonesian Society of Gastroenterology (ISG), in collaboration with PT. Eisai Indonesia, held a Scientific Expert Meeting titled “Real World Experience of Elobixibat as Chronic Constipation Treatment in Indonesia” on Sunday, June 1, 2025. The event brought together leading gastroenterology experts to discuss the effectiveness of Elobixibat in the management of chronic constipation.

The meeting featured two main sessions covering both theoretical perspectives and real-world clinical evidence on the use of Elobixibat.

In the first session, Prof. Ari Fahrial Syam, MD, MMB, PhD, FACP, FACG, explained the mechanism of action of Elobixibat as an IBAT (ileal bile acid transporter) inhibitor. By increasing intestinal fluid secretion and accelerating colonic transit, Elobixibat represents a new therapeutic option for chronic constipation patients who do not respond adequately to conventional laxatives.

The second session, led by Prof. Marcellus Simadibrata, MD, PhD, FACG, FASGE, presented real-world clinical cases of Elobixibat use in Indonesia, which demonstrated promising effectiveness.

Recommendations for the Use of Elobixibat in Chronic Constipation

The meeting resulted in a proposed algorithm for chronic constipation therapy, which includes the following recommendations:

• Elobixibat may be prescribed as monotherapy for patients without comorbidities for 10–14 days.
• Treatment should be evaluated on day 15, with dose adjustments based on response (increased to 15 mg once daily if necessary, or reduced in case of adverse effects).
• Combination therapy is recommended for patients with specific conditions or previous treatment failure with conventional laxatives.
• Possible combinations include Elobixibat with probiotics, stimulant or osmotic laxatives, or prokinetic agents, depending on clinical indications.
• For long-term management, Elobixibat can be continued for 1–4 months if effective, accompanied by a tapering strategy to help restore natural bowel movement patterns.

With a data-driven and clinically grounded approach, Elobixibat is expected to become a safe, effective, and practical treatment option for the management of chronic constipation in Indonesia.